S14G-Humanin (HNG): Humanin Analogue — Research Overview

S14G-humanin, also called HNG, is an analogue of the 24-residue humanin peptide with glycine replacing serine at position 14. Native humanin and HNG are distinct molecules; results should identify which was tested.

Xu et al. (2006) investigated the analogue in mouse focal cerebral ischemia/reperfusion experiments. Gao et al. (2017) studied oxygen–glucose deprivation/reoxygenation in a cell model, including PI3K/AKT and Jak2/Stat3 signaling. Peng et al. (2018) examined a murine MCAO model and brain endothelial cells. These are preclinical systems.

Zhang et al. (2009) examined S14G-humanin and beta-amyloid-associated long-term potentiation inhibition in mouse hippocampal slices. Niikura et al. (2011) studied S14G-humanin in triple-transgenic mice, reporting amyloid and memory-test findings. The tested derivative in that paper is the S14G analogue.

Ozgul et al. (2023) used HPLC and high-resolution mass spectrometry to investigate HNG stability in different solution matrices and storage conditions. They identified oxidation and dimerization products and found matrix- and condition-dependent loss of intact peptide. These findings motivate formulation-specific analytical checks; they do not supply a universal shelf life or certify the current product.

Cell, tissue-slice and mouse findings are model-specific and do not establish human neurological treatment effects. They do not certify the labeled 5 mg preparation. No human administration or dosing instructions are provided.